Study of high-risk kidney cancer patients
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at patients with kidney cancer that hasn't spread and is considered high-risk. It uses a registry to learn more about these patients to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with kidney cancer (renal cell carcinoma) that is localized or has not spread beyond the kidney, and is considered high-risk.
- You were included in the UroCCR registry between January 1, 2014, and December 31, 2023.
- You gave consent to participate in the UroCCR and UroCCR-Chain registries.
- You do not have cancer that has spread to other parts of the body (metastatic disease).
- You do not have inherited (hereditary) kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study enrolls people newly diagnosed with kidney cancer (including when it has spread) to help build research resources for future kidney cancer care. If you qualify, your information may be used to better understand outcomes and improve treatments.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.